康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CXO 康休

退市 08-10 17:41:31 EDT

65.60

+0.00

0.00%

最高65.60	最低65.60	成交量0.00
今开65.60	昨收65.60	日振幅0.00%
总市值127.60亿	流通市值126.27亿	总股本1.95亿
成交额0.00	换手率0.00%	流通股本1.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CXO","market":"US","secType":"STK","nameCN":"康休","latestPrice":65.6,"timestamp":1610744400000,"preClose":65.6,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":192489259,"shares":194506801,"eps":-52.266872,"marketStatus":"退市","change":0,"latestTime":"08-10 17:41:31 EDT","open":65.6,"high":65.6,"low":65.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-52.266872,"tradingStatus":0,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1786406400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1186113600000,"exchange":"NYSE","adjPreClose":65.6,"dividendRate":0.011052,"volumeRatio":0},"requestUrl":"/m/hq/s/CXO/wiki","defaultTab":"wiki","newsList":[{"id":"2657698357","title":"港股CXO近日股价集体走高，盈警之后的泰德医药(03880)将逆市下跌还是超跌反弹？","url":"https://stock-news.laohu8.com/highlight/detail?id=2657698357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657698357?lang=zh_cn&edition=full","pubTime":"2026-08-07 10:22","pubTimestamp":1786069332,"startTime":"0","endTime":"0","summary":"7月31日盘后，泰德医药发布了其26H1财年盈警公告。目前泰德医药尚未迎来连续数个交易日的低点逐步抬高以彻底终结下跌趋势，关键的量能均线也尚未出现明显转折。近日，港股医药概念股集体走高，CXO、创新药板块多点爆发，带动恒生医疗保健指数强势反弹。以8月4日行情为例，港股CXO板块出现一波个股集体走高，其中药明康德股价大涨11.17%，康龙化成和泰格医药均涨超5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","03880","NIFE","WX","BK1141","CXO","VXUS","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657002","title":"【券商聚焦】中信建投：CXO 行业复苏明确，海内外医药投融资同步回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657002","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657657002?lang=zh_cn&edition=full","pubTime":"2026-08-06 09:04","pubTimestamp":1785978243,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投表示，国内CXO行业经历22-24年的调整阶段后，受益海外投融资率先回暖，24年国内头部CXO公司海外订单展现复苏态势，随着25年国内创新药资产实现大规模对外授权，带动国内投融资25H2持续复苏，行业内需同样企稳回升。26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，该机构认为26年国","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987586","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1515","BK1574","BK0276","WX","601066","KCE","CXO","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572212","title":"中信建投：CXO板块Beta稳中向好，AI制药大有可为","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572212","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657572212?lang=zh_cn&edition=full","pubTime":"2026-08-06 07:41","pubTimestamp":1785973273,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ARTY","CXO","AIPO","QTOC","VTHR","CHAT","AGIX","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657591587","title":"CXO巨头爆量上涨！开盘45分钟成交120亿元，超上日全天！规模最大医疗ETF（512170）创本轮反弹新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2657591587","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657591587?lang=zh_cn&edition=full","pubTime":"2026-08-05 10:35","pubTimestamp":1785897300,"startTime":"0","endTime":"0","summary":"CXO巨头药明康德重磅财报继续发酵！8月5日早盘，药明康德A股爆量上行，盘初一度续涨逾6%，截至10：15涨4.6%，成交超120亿元，超越上日全天，跻身A股成交额前五！全市场规模最大医疗ETF华宝同步上扬，场内价格创本轮反弹新高！数据显示，药明康德为医疗ETF华宝第一大重仓股，最新持仓占比达12.69%。高效参与CXO交易，关注两大“利器”：医疗ETF华宝：全市场规模最大医药医疗类ETF，聚焦医疗器械+医疗服务，兼顾AI医疗概念。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-05/doc-inimfshm5200987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["512170","WX","CXO","159828"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656158919","title":"港股异动 | CRO概念股涨幅居前 近期多家海外MNC与CXO披露中报盈喜并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2656158919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656158919?lang=zh_cn&edition=full","pubTime":"2026-08-04 11:05","pubTimestamp":1785812703,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念股涨幅居前，截至发稿，药明康德涨11.05%，报180.9港元；金斯瑞生物科技涨10.18%，报17.96港元；凯莱英涨7.71%，报117.4港元；药明生物涨3.92%，报40.34港元。消息面上，药明康德公告称，上半年公司实现营业收入288.97亿元，同比增长38.93%；归母净利润110.8亿元，同比增长29.43%。值得注意的是，近期已有多家多家海外MNC与CXO披露中报盈喜并上调全年指引。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0708995583.HKD","LU0359202008.SGD","LU0588546209.SGD","LU0348767384.USD","BK1589","VXUS","KCAI","LU0516422440.USD","LU0052750758.USD","HK0000306685.HKD","LU1242518857.USD","01548","KURE","LU0043850808.USD","BK1576","LU0417516738.SGD","BK1521","LU0417516902.SGD","LU0456846285.SGD","LU0348766576.USD","LU1794554557.SGD","LU1688375341.USD","LU0456827905.SGD","LU0516423174.USD","BK1191","02269","SG9999002463.SGD","HK0000306701.USD","LU1046422090.SGD","LU1242518931.SGD","BK1610","BK4585","LU3063872942.SGD","LU0856984785.SGD","WX","LU0979878070.USD","BK1583","LU0516422952.EUR","06821","BK1141","LU0823426480.USD","LU0140636845.USD","LU0348825331.USD","02359","BK4588","LU0181495838.USD","LU0327786744.USD","LU0039217434.USD","CXO","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654095486","title":"医药外包概念全线扬升 昭衍新药(06127)涨7.93% 机构指CXO景气进入中报业绩兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2654095486","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654095486?lang=zh_cn&edition=full","pubTime":"2026-07-27 10:17","pubTimestamp":1785118673,"startTime":"0","endTime":"0","summary":"消息面上，开源证券新近研究指出，7月以来，康龙化成、昭衍新药、美迪西和药康生物先后发布2026年H1业绩预增公告，从早研到临床前研究，CXO景气周期已逐步进入利润表兑现期。根据医药魔方，2026H1全球创新药一级市场共发生505起融资事件，同比增长6.1%，融资金额达到267.5亿美元，同比增长58.5%。2026H1中国相关交易数量及金额涨势迅猛，总金额达997亿美元。从6月初至今，CXO板块在业绩和订单的支撑下，率先于创新药反弹。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986787","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU3063872942.SGD","603127","BK1589","HK0000320264.USD","KURE","LU2242644610.SGD","WX","LU0417516738.SGD","BK1574","LU0327786744.USD","LU0307460666.USD","BK1141","LU0348767384.USD","LU0348735423.USD","LU0823426308.USD","02359","CXO","LU0348766576.USD","SG9999002562.SGD","03347","LU0140636845.USD","LU0359201612.USD","LU1880383366.USD","BK1191","BK1583","01548","LU0588546209.SGD","LU0043850808.USD","06127","HK0000306685.HKD","LU0516422440.USD","01873","03759","BK1610","02269","LU0039217434.USD","LU2125910500.SGD","LU2039709279.SGD","LU0823426480.USD","LU0516423174.USD","LU0856984785.SGD","LU0516422952.EUR","LU1242518931.SGD","BK0216","159938","BK1161","LU1242518857.USD","09939","LU1046422090.SGD","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653270629","title":"中信建投：CXO板块Beta稳中向好 个股订单加速兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2653270629","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653270629?lang=zh_cn&edition=full","pubTime":"2026-07-24 13:46","pubTimestamp":1784871966,"startTime":"0","endTime":"0","summary":"26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，该行认为26年国内CRO/CDMO行业的新签订单及业绩会加速增长，带动CXO产业链进入新一轮发展阶段。随着资金由融资端向CXO逐级传导，叠加板块估值仍处历史较低水平，行业业绩与估值有望持续修复。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0276","WX","CXO","601066"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653772632","title":"中信建投：2026年国内CRO/CDMO行业的新签订单及业绩会加速增长，带动CXO产业链进入新一轮发展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2653772632","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653772632?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:20","pubTimestamp":1784852419,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CDMO","WX","BK4139","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651451783","title":"昭衍新药净利最高增13.8倍：CXO破冰，先从一群实验猴开始","url":"https://stock-news.laohu8.com/highlight/detail?id=2651451783","media":"港股研究社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651451783?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:48","pubTimestamp":1784108880,"startTime":"0","endTime":"0","summary":"7月15日昭衍新药在港股高开超过12%，可见资本市场对CXO盈利修复的敏感度非同一般。2025年年度报告显示，昭衍新药当年实现收入16.58亿元，同比下降17.9%，其中非临床研究服务收入15.77亿元，占总收入95.1%；综合毛利率由25.0%降至20.71%，同比下降7.72个百分点。昭衍新药与常规CXO公司不同，其实验猴价格上涨可以同时影响资产价值、项目报价和实验成本，使利润表带有较强的商品周期特征。昭衍新药已经给出CXO行业离开底部的证据，尚未给出全面上行的终局答案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-15/doc-inihwrra4796564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1141","BK0216","603127","BK1576","06127","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651272331","title":"港股异动 | CRO概念股今日普涨 内外需求共振行业向好 机构称CXO反弹具有业绩支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=2651272331","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651272331?lang=zh_cn&edition=full","pubTime":"2026-07-14 14:48","pubTimestamp":1784011706,"startTime":"0","endTime":"0","summary":"据报道称，当前食蟹猴身价已突破20万元。华鑫证券研报认为，从6月初至今，CXO板块在业绩和订单的支撑下，率先于创新药反弹。自6月8日至7月10日，CRO指数已反弹21.72%。展望下半年，创新药融资增长将继续支持CXO景气度延续。目前CRO龙头企业药明康德2027年预测PE为17.58X，凯莱英为33.19X。随着中期业绩临近，2季度订单趋势逐步明确，CXO反弹有望获得业绩支撑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU1046422090.SGD","02359","BK1576","06821","LU0348767384.USD","VXUS","BK1191","LU2242644610.SGD","BK1141","LU2045819591.USD","BK1583","03759","LU0348766576.USD","LU2125910500.SGD","LU0708995583.HKD","06127","LU0052750758.USD","BK4588","LU0320764599.SGD","CXO","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651386126","title":"医药外包概念股普涨 凯莱英(06821)升逾4% 机构指CXO反弹有望获业绩支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=2651386126","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651386126?lang=zh_cn&edition=full","pubTime":"2026-07-14 10:51","pubTimestamp":1783997504,"startTime":"0","endTime":"0","summary":"2026年Q2Orforglipron等外企重磅品种获批上市，继续支撑药明康德订单增长。药明康德主动回购也彰显对未来信心，截止2026年6月25日，已回购金额超过10亿元。从6月初至今，CXO板块在业绩和订单的支撑下，率先于创新药反弹。自6月8日至7月10日，CRO指数已反弹21.72%。展望下半年，创新药融资增长将继续支持CXO景气度延续。目前CRO龙头企业药明康德2027年预测PE为17.58X，凯莱英为33.19X。随着中期业绩临近，2季度订单趋势逐步明确，CXO反弹有望获得业绩支撑。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985793","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU1720050803.USD","BK1576","LU0856984785.SGD","LU0979878070.USD","LU0326950275.SGD","BK1515","002821","LU0823426480.USD","LU0051755006.USD","SG9999002463.SGD","LU0516423091.SGD","BK1191","BK1521","IE00B0JY6N72.USD","BK1574","LU0348735423.USD","LU0348825331.USD","LU0516422952.EUR","KURE","LU1794554557.SGD","LU3063872942.SGD","03347","BK0239","CXO","06127","LU0043850808.USD","BK1161","06821","LU0181495838.USD","BK0132","LU0516423174.USD","LU2045819591.USD","02269","LU2242644610.SGD","LU0039217434.USD","LU0708995583.HKD","02359","LU1688375341.USD","159938","09939","LU0516422366.SGD","LU1046422090.SGD","LU2125910500.SGD","03759","LU0456827905.SGD","LU1242518857.USD","LU0417516738.SGD","LU0327786744.USD","LU0456846285.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649995950","title":"大和：首予药明合联(02268)“买入”评级 列CXO首选","url":"https://stock-news.laohu8.com/highlight/detail?id=2649995950","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649995950?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:40","pubTimestamp":1783482019,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大和发布研报称，首次给予药明合联“买入”评级，目标价78港元，并列为中国CXO行业首选股之一，指出药明合联是全球领先的抗体药物偶联物合约研究、开发及生产组织，亦是全球最大的纯ADC CRDMO企业，2025年市场份额达24%，预期受惠于快速增长的ADC外包市场及公司全链条CRDMO服务能力，该公司将能持续取得更多市场份额。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649920610","title":"生物科技板块全面走强 生物科技ETF易方达涨2.91%，康龙化成、泰格医药涨超5%领涨CXO赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2649920610","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649920610?lang=zh_cn&edition=full","pubTime":"2026-07-06 11:07","pubTimestamp":1783307249,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ARTY","BK4581","BK4585","SYNB","FDN","GDOC","XBI","CXO","MEDX","BK4550","BK4588","XLK","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645815572","title":"药明康德今日大涨，一度“封板” 机构：创新药、CXO赛道迎估值修复行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2645815572","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645815572?lang=zh_cn&edition=full","pubTime":"2026-06-24 21:04","pubTimestamp":1782306277,"startTime":"0","endTime":"0","summary":"6月24日，A股、港股CXO（医药外包）及创新药板块迎来强势反弹行情，该板块个股集体冲高。其中，龙头股药明康德（SH603259）A股盘中强势涨停，一度“封板”，下午开盘后打开涨停板，报收115.40元/股，上涨8.55%。此外，凯莱英（SZ002821）也拉涨停“封板”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606243781645287.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606243781645287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2328871848.SGD","BK0216","LU0052750758.USD","LU1046422090.SGD","LU2242644610.SGD","LU1979443071.USD","BK1576","LU1251922891.USD","LU0320764599.SGD","LU1770034418.SGD","BK1161","LU2495084118.USD","LU1934453819.USD","IE00B543WZ88.USD","LU1997245094.SGD","603259","LU0708995583.HKD","159992","LU1997245177.USD","BK1574","LU1719994722.HKD","LU2045819591.USD","LU1303224171.USD","CXO","LU0456842615.SGD","LU0348767384.USD","BK1583","BK1141","LU2488822045.USD","02359","IE00BPRC5H50.USD","LU1969619763.USD","IE00B5MMRT66.SGD","LU1808992512.USD","LU0348766576.USD","LU1997244956.HKD","06978","LU2125910500.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645897118","title":"CXO成反弹急先锋？高CXO含量港股通医疗ETF华宝（159137）盘中劲涨5.44%！创新药同步回血，520880上探4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645897118","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645897118?lang=zh_cn&edition=full","pubTime":"2026-06-24 19:26","pubTimestamp":1782300360,"startTime":"0","endTime":"0","summary":"6月24日，港股通医药久违大涨，创新药产业链强劲反攻！CXO一马当先：凯莱英狂飙13.12%，金斯瑞生物科技涨11.5%紧随其后，药明系权重龙头药明合联、药明康德、药明生物分别收涨8.88%、8.33%、4.17%。　　港股通医疗ETF华宝超四成仓位布局CXO龙头，盘中最高涨幅达5.44%尽显高弹性，收涨4.35%连收5日及10日均线，成交6531万元创近4个月新高！　　中报季临近，多家机构重点提示CXO板块投资机会，其中华福证券明确表示，重视CXO全年战略配置价值，并给出三点依据：","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-06-24/doc-iniepeiq1495055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","520880","512170","159137","BK4588","BK1161","159992","VXUS","BK1574","BK4585","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645866019","title":"CXO概念走强 凯莱英 (06821) 涨 17.77% BIO2026大会看好中国CXO高效率优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2645866019","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645866019?lang=zh_cn&edition=full","pubTime":"2026-06-24 11:17","pubTimestamp":1782271026,"startTime":"0","endTime":"0","summary":"全球生物技术领域盛会BIO2026大会于6月22日至25日在美国圣地亚哥召开，汇聚全球超20000名行业参与者，覆盖人工智能与数字健康、细胞与基因治疗等前沿领域，中国CXO企业的高效率优势备受关注。光大证券研报指，2026年6月22日至25日BIO2026大会举办，70余个国家超2万名业内人士参会，覆盖18大生物医药核心议题，凯莱英、泰格医药、博腾股份等国内CXO企业参展，英硅智能同期落地AI药物研发海外合作。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984377","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0327786744.USD","LU0516422952.EUR","LU0456827905.SGD","LU1328615791.USD","LU1880383366.USD","LU2039709279.SGD","HK0000320223.HKD","LU0051755006.USD","LU0456846285.SGD","LU0348766576.USD","LU1242518931.SGD","06127","LU0359202008.SGD","03759","02269","LU0708995583.HKD","LU1046422090.SGD","02359","LU3063872942.SGD","LU0052750758.USD","06821","SG9999002463.SGD","01548","BK0132","BK1521","002821","LU0320764599.SGD","CXO","LU0348735423.USD","LU1794554557.SGD","LU0516422366.SGD","LU2242644610.SGD","HK0000320264.USD","03347","LU0359201612.USD","BK0239","LU1720050803.USD","LU0588546209.SGD","LU0039217434.USD","HK0000306685.HKD","LU0043850808.USD","LU0856984785.SGD","BK1576","LU0326950275.SGD","BK1583","LU0140636845.USD","LU0572944931.SGD","LU0819121731.USD","HK0000306701.USD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645653708","title":"港股异动 | CRO概念股表现强势 BIO大会凸显中国CXO全球竞争力 医药领域开放迎来新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2645653708","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645653708?lang=zh_cn&edition=full","pubTime":"2026-06-24 10:00","pubTimestamp":1782266401,"startTime":"0","endTime":"0","summary":"消息面上，BIO 2026国际生物科技大会于6月22日至25日在美国圣地亚哥召开，中国CXO企业的高效率优势得到全球认可，海外订单拓展空间进一步打开。东方证券发布研报称，从CXO景气度关键指标的最新数据来看：2026年前五个月，国内资金端、研发端、订单端多重因素共振向上，国内CXO行业高景气持续。该行认为，国内CXO公司订单充足、量价双升，随着订单执行转化，将会带来报表端大幅改善。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK4588","HK0000320264.USD","LU1169589451.USD","LU0348767384.USD","LU0320764599.SGD","BK1515","LU2045819591.USD","BK1583","09939","HK0000306685.HKD","BK1574","03347","LU0052750758.USD","01548","LU1169590202.USD","06821","HK0000320223.HKD","159938","LU2242644610.SGD","LU2125910500.SGD","BK1161","BK4585","BIO","LU1046422090.SGD","HK0000306701.USD","CXO","VXUS","BK1191","BK4121","LU0348766576.USD","BK1576","02359","LU0708995583.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640468995","title":"方正证券：坚守创新药和CXO 关注跨界公司的超额成长性","url":"https://stock-news.laohu8.com/highlight/detail?id=2640468995","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640468995?lang=zh_cn&edition=full","pubTime":"2026-06-02 09:16","pubTimestamp":1780363008,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，方正证券发布研报称，今年以来医药板块表现相对平淡，去年创新药BD情绪带动子板块超额修复，今年陆续进入兑现期，部分兑现度较差的公司拖累了指数表现，但该行仍然认为创新药出海是目前医药板块中最重要的成长方向，仍然需要坚守创新药及CXO板块，此外受科技整体周期的情绪拉动，部分医药跨界AI基建的公司也有超额表现，适当关注拥有跨界业务的耗材板块。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0122","601901","159992","BK1574","BK0028","BK0012","BK0183","BK1161","06978","BK0276","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635406847","title":"A股药企突遭国际巨头4.3亿元索赔，20 厘米跌停，撕开 CXO 出海隐痛","url":"https://stock-news.laohu8.com/highlight/detail?id=2635406847","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635406847?lang=zh_cn&edition=full","pubTime":"2026-05-16 17:51","pubTimestamp":1778925084,"startTime":"0","endTime":"0","summary":"A股药企博腾股份突发重大海外纠纷，旗下欧洲基地被国际巨头单方面解约，且被索要4.3亿元巨额赔偿。利空消息一出，该股开盘直接20厘米跌停，在资本市场引发剧烈震动。这家曾靠新冠订单一战成名的小分子CDMO龙头，四年间走完一轮完整的业绩大起大落：从年净利润超20亿元的高光巅峰，一路回落陷入亏损泥潭，2025年刚实现扭亏企稳，又深陷海外合约风波、巨额索赔与股价重挫的多重压力之中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605163739616550.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605163739616550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159982","CXO","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635076637","title":"国金证券：CXO内外需共振向上 新分子赋能行业持续扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2635076637","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635076637?lang=zh_cn&edition=full","pubTime":"2026-05-14 10:35","pubTimestamp":1778726116,"startTime":"0","endTime":"0","summary":"CXO行业进入内外需共振、新分子赛道放量、订单与业绩逐季改善的新一轮复苏上行周期。从海外CXO龙头企业的经营业绩与业绩指引调整趋势来看，2025年多家海外CXO公司逐季度上调全年业绩预期，盈利修复节奏持续超市场预期。展望2026年，海外头部CXO企业收入指引仍维持稳健小幅增长格局，叠加全球生物医药投融资逐步回暖、创新药研发需求稳步复苏，行业景气度延续上行态势，成长确定性进一步增强。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0012","BK0183","600109","BK0276","CXO","BK0201","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.concho.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Concho Resources Inc.成立于2006年2月22日，是一家于2006年2月在特拉华州注册成立的公司，是一家独立的石油和天然气公司，从事石油和天然气资产的收购、开发、勘探和生产。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.054246},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.002949},{"month":3,"riseRate":0.692308,"avgChangeRate":0.024071},{"month":4,"riseRate":0.769231,"avgChangeRate":0.069872},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.030229},{"month":6,"riseRate":0.461538,"avgChangeRate":0.004495},{"month":7,"riseRate":0.692308,"avgChangeRate":0.012949},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.02419},{"month":9,"riseRate":0.571429,"avgChangeRate":0.015298},{"month":10,"riseRate":0.5,"avgChangeRate":0.017047},{"month":11,"riseRate":0.571429,"avgChangeRate":0.047858},{"month":12,"riseRate":0.642857,"avgChangeRate":0.007299}],"exchange":"NYSE","name":"康休","nameEN":"Concho Resources"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康休,CXO,康休股票,康休股票老虎,康休股票老虎国际,康休行情,康休股票行情,康休股价,康休股市,康休股票价格,康休股票交易,康休股票购买,康休股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}